MDxHealth (NASDAQ: MDXH) is a precision diagnostics company specializing in urology. The company is currently undergoing a significant strategic shift. It is discontinuing its Resolve UTI testing business and closing a laboratory facility to sharpen its focus on its core prostate cancer diagnostics business.
On May 13, 2026, MDxHealth reported an earnings per share (EPS) of -$0.19, which missed the consensus analyst estimate of -$0.14. EPS represents the company's profit allocated to each outstanding share of stock. A negative figure, like MDxHealth's, means the company experienced a net loss during the quarter.
The company also announced revenue of $23.90 million, falling short of the estimated $30.89 million. As highlighted by GlobeNewswire, this financial performance coincides with the strategic exit from the UTI business. CEO Michael McGarrity stated this move was due to an "increasingly uncertain reimbursement landscape" for the Resolve test.
The company's financial health reflects its lack of profitability, with a Price-to-Earnings (P/E) ratio of -2.91. A negative P/E ratio occurs when a company has negative earnings, or a net loss. This is further shown by its negative earnings yield of -34.36%, which compares the company's losses to its share price.
MDxHealth's balance sheet shows a Debt-to-Equity ratio of -7.86, indicating it has negative shareholder equity. This happens when a company's total liabilities exceed its total assets. However, its current ratio of 1.08 suggests its current assets are just sufficient to cover its short-term liabilities.
